galantamine hydrobromide
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia, Pick Complex
Trial Timeline
May 1, 2003 → Jul 1, 2004
NCT ID
NCT00416169About galantamine hydrobromide
galantamine hydrobromide is a phase 2 stage product being developed by Johnson & Johnson for Frontotemporal Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT00416169. Target conditions include Frontotemporal Dementia, Pick Complex.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00253201 | Phase 3 | Completed |
| NCT00416169 | Phase 2 | Completed |
| NCT00240695 | Phase 3 | Completed |
| NCT00236431 | Phase 3 | Completed |
| NCT00236574 | Phase 3 | Completed |
| NCT00253214 | Phase 3 | Completed |
| NCT00261573 | Phase 3 | Completed |
| NCT00253227 | Phase 3 | Completed |
| NCT00253188 | Phase 3 | Completed |
| NCT00338117 | Phase 3 | Completed |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone | Eli Lilly | Phase 1/2 | 41 |
| memantine hydrochloride | Lundbeck | Phase 3 | 74 |
| Syntocinon | Brain Biotech | Phase 2 | 44 |
| DNL593 + Placebo | Denali Therapeutics | Phase 1/2 | 36 |
| PBFT02 | Passage Bio | Phase 1/2 | 33 |